| Previous Close | 43.70 |
| Open | 43.78 |
| Bid | 43.98 x 600 |
| Ask | 44.07 x 100 |
| Day's Range | 44.07 - 44.19 |
| 52 Week Range | 36.58 - 47.82 |
| Volume | 8,530 |
| Avg. Volume | 77,436 |
| Net Assets | 451.95M |
| NAV | 43.04 |
| PE Ratio (TTM) | N/A |
| Yield | 0.61% |
| YTD Return | 10.38% |
| Beta (3y) | 1.25 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2006-06-19 |
- Market Realist•6 days ago
Understanding Allergan’s Revenue Stream for 2017
Allergan's revenues are driven by the strong performance of products under its key brands as well as the inclusion of revenues from LifeCell and other acquisitions.
- MarketWatch•9 days ago
This week could be make or break for the GOP health care bill
After months of debates over the Republican party’s health bill, the end of this week is “probably make or break” for the effort, EvercoreISI analyst Terry Haines said Tuesday. It could also affect the ...
- Zacks•10 days ago
What Lies Ahead for Pharma ETFs in Second Half 2017
We discuss some of the factors that could contribute to a sustained recovery in the sector.
